In8Bio (INAB) Total Current Liabilities (2020 - 2026)
In8Bio (INAB) posted Total Current Liabilities of $2.2 million for Q1 2026, down 31.73% sequentially from $3.2 million in Q4 2025, and down 27.02% YoY from $3.0 million in Q1 2025.
In8Bio (INAB) Total Current Liabilities (2020 - 2026) Analysis & Trends
In8Bio has reported Total Current Liabilities for 7 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Total Current Liabilities fell 27.02% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 27.02% YoY) and the FY2025 annual result came in at $3.2 million, up 2.53% from the prior year.
- Total Current Liabilities eased to $2.2 million in Q1 2026 per INAB's latest filing, from $3.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.8 million in Q4 2022 and troughed at $1.7 million in Q3 2025.
- A 5-year average of $3.5 million and a median of $3.4 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 158.07% in 2022, then plunged 58.94% in 2025.
- Over 5 years, Total Current Liabilities stood at $5.8 million in 2022, then slipped by 7.37% to $5.4 million in 2023, then slumped by 42.83% to $3.1 million in 2024, then climbed by 2.53% to $3.2 million in 2025, then slumped by 31.73% to $2.2 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.2 million, $3.2 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.25 Mn |
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | 2.96 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 3.64 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Dec 31, 2023 | 5.39 Mn |
| Sep 30, 2023 | 4.69 Mn |
| Jun 30, 2023 | 3.78 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 4.90 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | 2.07 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 2.16 Mn |
| Jun 30, 2021 | 2.77 Mn |